Cannabis Science, Inc. (CBIS) to Release 8 Initial Cannabis-Based Products, Synergistically Produced, Distributed and Marketed Across California, Spain, and the Netherlands, For Pre-Clinical Studies and Immediate Self-Medicating Patient Usage for Critical Ailments
COLORADO SPRINGS, Colo., Jan. 5, 2015 /PRNewswire/ — Cannabis Science, Inc. (CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce the International release of 8 initial products that will be synergistically produced, distributed and marketed across the Netherlands, Spain and California where Cannabis Science is active and has cannabis production facilities.
The products are currently ready for pre-clinical studies, self-medicating patient ailment usage, marketing release, sales and distribution. The roll-out will involve Cannabis Science teams in both Europe and California to work in tandem to share information, send formulations to be produced in each respective production facility and share patient indicators based on usage metrics to scale demand, while collecting insightful data in each geographical market appropriately. Different logistical capabilities will be developed through internal management to adequately produce, distribute and market products along with the proper procurement of opt-in, informed consent patient data from outcomes to establish Cannabis Science with a vertically integrated product pipeline to accommodate international markets.
Cannabis Science will be announcing shortly where products are available for purchase in each jurisdiction; initial cannabis formulations will be focused on:
- Topical formulations for cancers
- Ingestible formulations for cancers, HIV/AIDS and other indications
- Varied formulations for neurological disorders and other indications depending on delivery methodology required
- Ingestible and topical formulations for chemotherapy side effects, chronic pain, muscle problems, sleeping disorders, nausea, ADHD, rheumatism, arthritis, infections, diabetes, manic depression, fibromyalgia and other issues
- Topical formulations for rheumatism, fibromyalgia, arthritis, eczema, sporting injuries, radiotherapy wounds, muscle and neck pain, radiotherapy wounds, rheumatism, open wounds and sensitive and irritated skin, various skin complaints, and wounds
The Cannabis Science Patient Access Center (PAC) https://pac.cannabisscience.com, released in beta version, is now available for patients to track usage and receive updates.
“With the proper distribution channels in place to reach large ranges of patients in different prognosis situations, we intend on releasing our cannabis formulations with specific support channels and applications to provide consumers adequate insight into product specifications, usage recommendations and the opt-in ability to input a variety of sentiments across medical indicators for the appropriate monitoring of effects. Our Scientific Advisory Board and management team is working towards the development of a vertically integrated model to standardize aforementioned practices for multiple other jurisdictions and regulatory environments to accommodate the growth of the sector,” stated Mr. Raymond C. Dabney, Director, President & CEO, Co-Founder, Cannabis Science, Inc.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science, Inc.
Raymond C. Dabney, Director, President & CEO, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788
Chad S. Johnson, Esq., Director, COO, & General Counsel
www.cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658
To view the original version on PR Newswire, visit:https://www.prnewswire.com/news-releases/cannabis-science-inc-cbis-to-release-8-initial-cannabis-based-products-synergistically-produced-distributed-and-marketed-across-california-spain-and-the-netherlands-for-pre-clinical-studies-and-immediate-self-medicating-p-300015686.html
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
1 comment